Dalbavancin in the treatment of different gram-positive infections: a real-life experience
- 24 November 2017
- journal article
- research article
- Published by Elsevier BV in International Journal of Antimicrobial Agents
- Vol. 51 (4), 571-577
- https://doi.org/10.1016/j.ijantimicag.2017.11.008
Abstract
No abstract availableThis publication has 36 references indexed in Scilit:
- Efficacy of daptomycin in the treatment of enterococcal endocarditis: a 5 year comparison with conventional therapyJournal of Antimicrobial Chemotherapy, 2014
- Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children: Executive SummaryClinical Infectious Diseases, 2011
- Distribution of Radioactivity in Bone and Related Structures following Administration of [ 14 C]Dalbavancin to New Zealand White RabbitsAntimicrobial Agents and Chemotherapy, 2007
- Randomized, Double-Blind Comparison of Once-Weekly Dalbavancin versus Twice-Daily Linezolid Therapy for the Treatment of Complicated Skin and Skin Structure InfectionsClinical Infectious Diseases, 2005
- Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptideJournal of Antimicrobial Chemotherapy, 2005
- Causal Relationship between Neuropathy and Prolonged Linezolid UseClinical Infectious Diseases, 2004
- Tolerability, Pharmacokinetics, and Serum Bactericidal Activity of Intravenous Dalbavancin in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2004
- Once-Weekly Dalbavancin versus Standard-of-Care Antimicrobial Regimens for Treatment of Skin and Soft-Tissue InfectionsClinical Infectious Diseases, 2003
- Linezolid-Associated Toxic Optic Neuropathy: A Report of 2 CasesClinical Infectious Diseases, 2003
- CDC definitions for nosocomial infections, 1988American Journal of Infection Control, 1988